Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in extensive stage small cell lung cancer
NCT03066778Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2017
- Primary completion
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 19
01
Overview
A Phase 3 trial of pembrolizumab in small cell lung cancer (SCLC), sponsored by Merck & Co.. Started May 2017; status: completed.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03066778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03066778.